Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01982201 · ClinicalTrials.gov registry record · Phase 1
Antacid Interaction Study
A Phase 1 study, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01982201 is a Phase 1 study that has completed, run by Ardea Biosciences. The registered enrollment target is 24 participants.
The verdict
NCT01982201, a Phase 1 study, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will assess the potential effects of calcium carbonate and aluminum/magnesium hydroxide-containing antacids on the pharmacokinetics (PK) and pharmacodynamics (PD) of lesinurad in healthy, adult male subjects.
Interventions
- DRUG Lesinurad 400 mg
- DRUG Tums 500 mg and 750 mg
- DRUG MINTOX 10 mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01982201
The ClinicalTrials.gov registry entry for NCT01982201 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ardea Biosciences, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lesinurad 400 mg is the first listed.
NCT01982201 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01982201 about?
NCT01982201 is a clinical study titled "Antacid Interaction Study". This study will assess the potential effects of calcium carbonate and aluminum/magnesium hydroxide-containing antacids on the pharmacokinetics (PK) and pharmacodynamics (PD) of lesinurad in healthy, adult male subjects.
What is the current status of trial NCT01982201?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-11. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01982201?
The interventions under investigation include: Lesinurad 400 mg (DRUG), Tums 500 mg and 750 mg (DRUG), MINTOX 10 mL (DRUG).
Who is sponsoring clinical trial NCT01982201?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.